Skip to main content

Home/ health information/ Group items tagged pharmacy-news-uk

Rss Feed Group items tagged

1More

Chiesi Farmaceutici acquires Amryt Pharma - 0 views

  •  
    Chiesi Farmaceutici, the international, research-focused biopharmaceuticals and healthcare group has acquired Amryt Pharma, a global biopharmaceutical company dedicated to developing novel treatments for rare diseases. More than 300 million people worldwide are affected by rare diseases, including those who are living with ultra-rare metabolic and dermatologic conditions who still have no approved treatment. The acquisition reinforces Chiesi's commitment to deliver innovative treatments to patients with highly unmet medical needs. As a benefit corporation and a B Corp, Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. Chiesi's Head of Chiesi Global Rare diseases Giacomo Chiesi commented: "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development." Chiesi's new CEO Giuseppe Accogli said: "By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases." With regard to the financing of the deal, cash consideration has been partially financed through a EUR 700m syndicated loan led by BNP Paribas and Crédit Agricole as Global Coordinators and ESG Structuring Banks, acting alongside BPER and Deutsche Bank as Mandated Lead Arrangers. Crédit Agricole is Loan Agent too. Lenders have been advised by Clifford Chance, while Baker and McKenzie has assisted Chiesi Farmaceutici.
1More

UK Government Empowers Medical Associates in NHS Transformation - 0 views

  •  
    The UK government will lay legislation today (13 December 2023) to allow the General Medical Council (GMC) to begin the process of regulating medical associates to expand their roles in the NHS. This will support plans to reduce pressure on doctors and GPs and improve access for patients, the Department of Health and Social Care (DHSC) said. Physician associates (PAs) and anaesthesia associates (AAs) will have the same levels of regulatory oversight and accountability as doctors and other regulated healthcare professionals once the regulations come into force, which is expected at the end of 2024. The GMC will design and deliver detailed regulatory processes for registration, education, standards and fitness to practise for both professions.
1More

Massive Wastage: Over 1.5M Expired Pfizer Paxlovid Courses in Europe - 0 views

  •  
    More than 1.5 million courses of Pfizer's COVID-19 antiviral drug Paxlovid have expired unused in European countries by the end of November, the health analytics firm Airfinty has revealed. It is predicted that the figure could surge to 3.1 million, at a value of $2.2 billion (around £1.73 billion), by the end of Feb 2024. According to Airfinty analysis, Britain has the highest unused stock, with an estimated one million expired drug courses worth $700 million (over £550 million). With 2.2 million courses estimated to expire unused by the end of June 2024 due to the low prescription of the antiviral in the country, the total drug value wasted in the UK could reach $1.5 billion (£1.1 billion), the report added.
1More

Coeliac Crisis: NHS West Yorkshire's Gluten Free Prescription Cut Sparks Concerns - 0 views

  •  
    NHS West Yorkshire Integrated Care Board (ICB)'s decision to withdraw gluten free prescriptions for people with coeliac disease across Leeds and Calderdale has disappointed Coeliac UK. In a statement released on Thursday, the charity, which provides support and advice to those living with the disease, has raised "grave concerns" about the decision, warning that it will have a detrimental impact on the coeliac community. The policy is currently implemented across the ICB's other places including Bradford district and Craven, Kirklees and Wakefield district, preventing coeliac patients from accessing gluten free bread and flour mix on prescription. NHS West Yorkshire ICB wants to align its gluten free prescribing guidelines across its five places. But the charity is worried that the additional cost of gluten free staple products will poses a real challenge to maintaining the gluten-free diet, which is the only treatment for the condition.
1More

Revolutionizing ED Treatment: Eroxon Gel Hits Shelves - 0 views

  •  
    The UK based Pharma giant Futura Medical Plc's lead product, Eroxon, a topical Stim-gel is now available on NHS prescription in England and Wales for the treatment of Erectile Dysfunction (ED). The Muti-Drug Resistant (MDR) approved alternative to PDE5i, Eroxon is available as an over-the counter off shelf at retailers like Boots and Superdrug; and is available on NHS prescription in England and Wales as a CE-marked medical device. Erectile dysfunction (ED), also known as impotence, is the inability to get and maintain an erection, typically concerning men over the age of 40 due to both, psychological and physical causes such as anxiety, depression, diabetes, and obesity. According to UK Conformity Assessed (UKCA), the approval of the medication is based on evidence from 2 Phase three clinical studies, which showed that 60 per cent of patients taking Eroxon achieved Minimal Clinically Important Differences (MCID) at 12 weeks.
1More

South East leads in quitting smoking in the UK - 0 views

  •  
    Online vape store GoSmokeFree analysed data from NHS Stop Smoking Service in England from April to September 2023 to determine the number of individuals in each of the nine UK regions who reported successfully quitting smoking after setting a quit date. The findings showed that the South East has the highest number of successful quitters, with 1,226 smokers per 100,000 reporting to have given it up. The Isle of Wight is the most successful area to quit smoking in the South East with 3,124 people quitting per 100,000 smokers. Of the 4,294 individuals who set a quit date in this region, 803 admitted to not being able to achieve their target. A spokesperson from the online retailer noted that overcoming nicotine withdrawals and mental challenges can be exceptionally difficult when attempting to quit smoking.
1More

JAS Healthcare Unit Granted WDA(H) License for Pharma Excellence - 0 views

  •  
    Global logistics company, JAS has received the Wholesale Distribution Authorisation (WDA(H)) license from the UK's Medicine and Healthcare Products Regulatory Agency (MHRA) for its Pharma and Healthcare Division. In a press release issued on Thursday (22 February), the company said that securing the license empowers its UK healthcare division to "seamlessly connect" with its more than 40 GDP (Good Distribution Practice) certified overseas stations, strengthening its capabilities for handling pharmaceutical shipments. Headquartered in Atlanta, Georgia, USA, the company boasts a team of over 7,000 professionals, with operations spanning over 100 countries. Adrian Frodsham, Regional Director for JAS, said that they were granted the WDA(H) license after a "stringent audit process." "JAS UK's pharma and healthcare division prides itself of offering innovative solutions for the international delivery of pharmaceutical products, further enhancing the growth of our pre-established healthcare division," he added.
1More

Health & Care Work Visas Skyrocket 91% UK - 0 views

  •  
    Britain almost doubled the number of visas awarded to foreign migrants coming to work in the health and care sector last year, government data showed, adding to pressure on prime minister Rishi Sunak over immigration ahead of the next general election. Immigration is one of the top three concerns for voters as the country gears up for an election expected later this year. Trailing the opposition Labour party in the polls, Sunak has vowed to bring it down. But data released on Thursday by Home Office was the latest set of statistics to show the scale of the challenge he faces. Britain granted 337,240 work visas in 2023, 26 per cent higher than in 2022, with the rise largely driven by those coming to the country to work in the care home sector. That follows figures released in November which showed annual net migration to the UK hit a record 745,000 in 2022 and has stayed high since. Visas under the 'Skilled Worker - Health and Care' route almost doubled, Thursday's data showed, rising by 91 per cent to 146,477 last year.
1More

Join the Trainee ACTNow Wellbeing Campaign: May 20-24 - 0 views

  •  
    Trainee pharmacists across Great Britain are preparing to participate in Pharmacist Support's annual Trainee ACTNow Wellbeing Campaign, scheduled from May 20th to 24th. Organised by the charity, this initiative aims to provide essential support as trainees approach the culmination of their placements and gear up for the General Pharmaceutical Council (GPhC) assessment. Danielle Hunt, Chief Executive of Pharmacist Support, highlighted the campaign's focus on addressing the significant stress and pressure trainees may experience during this critical period. She stated: "We understand the anxiety and pressure they may feel, not only in preparing for the assessment but also in stepping into their roles as registered pharmacists."
1More

Nearly 150,000 Died on NHS Waiting Lists in England - Labour Analysis - 0 views

  •  
    A Labour Party analysis of NHS trust figures has revealed that around 148,000 people died last year while waiting for treatment in England. This is more than double the figure recorded in 2017/18, which stood at around 60,000 deaths. It even surpasses the mortality rate observed in 2021, during the peak of the Covid pandemic. The Labour Party obtained the data through a freedom of information request sent to every NHS trust in England. Out of the 169 acute and community trusts contacted, 80 responded. The total number of deaths reported by the respondents was 61,396. Extrapolating this figure to all trusts would suggest a total of 148,227 deaths.
1More

Labour pledges support for small businesses, plans overhaul of business rates - 0 views

  •  
    As the general election campaign continues, Labour is set to introduce a series of policies aimed at supporting small businesses. On Saturday, Sir Keir Starmer, alongside shadow chancellor Rachel Reeves and other shadow cabinet ministers, is expected to unveil the party's plans for the sector. Key proposals include an overhaul of the business rates system to enable high street shops to compete with online giants and ensure access to high street banking services by accelerating the establishment of banking hubs. Labour will also commit to addressing the issue of late payment of invoices by requiring large businesses to disclose their payment practices and "revitalise" high streets by tackling antisocial behaviour. Sir Keir described small businesses as "the beating heart of driving growth and creating jobs for local people."
1More

Half a million more at risk of type 2 diabetes in England in one year - 0 views

  •  
    The number of people in England identified as at risk for type 2 diabetes mellitus (T2DM) has increased by over half a million within a year, according to NHS figures. Data released by the National Diabetes Audit on June 12 showed that 3.6 million people registered with a GP were found to have non-diabetic hyperglycaemia (also known as pre-diabetes) in 2023, compared with 3.1 million people in 2022 - a notable 18 per cent increase or nearly 550,000 people. Among those under 40 years old, the figures showed an increase of almost 25 per cent from 173,166 in 2022 to 216,440 in 2023. People with non-diabetic hyperglycaemia have higher-than-normal blood sugar levels, and they are at greater risk for developing type 2 diabetes and cardiovascular diseases. Typically, this condition is detected through routine blood tests at GP surgeries.
1More

Empower Pharmacist to Prescribe: Exploring Labour Promising Policy 2024 UK - 0 views

  •  
    Healthcare reform emerged as a cornerstone of the Labour Party's manifesto leading up to the recent general election. A standout pledge was the establishment of a Community Pharmacist Prescribing Service, aimed at granting pharmacists independent prescribing rights where clinically suitable. This initiative is seen as a positive step in addressing critical challenges within the National Health Service (NHS). Numark Chairman Harry McQuillan praised Labour's recognition of pharmacists' role in patient care through expanded prescribing rights. "Let's be honest, pharmacists are an underutilised resource within the healthcare system. We possess extensive training and expertise, yet our full potential hasn't always been acknowledged. "By harnessing pharmacists expanded prescribing rights, Labour is acknowledging our significant role in patient care. This initiative aims to recognise our skills and enhance patient care, ensuring quicker access to necessary treatments," he said. However, he pointed out that the concept requires further exploration, as the rights to prescribe are already granted through the recent change to undergraduate training that incorporates prescribing.
1More

NHS in Crisis 2024 : Record A&E Attendances and Urgent Need for Action - 0 views

  •  
    The National Health Service(NHS) has reported a record number of attendances at Accident & Emergency (A&E) departments and emergency admissions for any June, reflecting significant pressure on healthcare services amidst hot weather and recent strikes by junior doctors. Last month, hospitals across the UK handled over 2.29 million A&E attendances and more than 536,884 emergency admissions, marking increases of 3.1 per cent and 7.2 per cent respectively compared to the previous year. Professor Sir Stephen Powis, NHS national medical director, acknowledged the strain on frontline teams: "Frontline teams are continuing to work exceptionally hard under significant pressure to provide the best care they can for patients."
1More

Groundbreaking Relief: NICE-Endorsed Atogepant for Migraines - 0 views

  •  
    Patients suffering from chronic and episodic migraine attacks are set to benefit from a groundbreaking recommendation by the National Institute for Health and Care Excellence (NICE) regarding a new medication. The atogepant, a first-of-its-kind preventive drug for migraine, offers hope for those grappling with this debilitating condition and can be taken orally. Published as part of the final guidance draft, NICE has greenlit the atogepant, also known as Aquipta and manufactured by AbbVie, as an option for preventing both chronic and episodic migraines in adults. Specifically, this recommendation is for individuals who have experienced at least four migraine days per month and have failed to find relief with at least three previous preventive treatments. With approximately 4.5 million people in the UK affected by various forms of migraine, this new recommendation marks a significant advancement in migraine management as the condition significantly impacts patients' day-to-day activities as well as places a heavy burden on the NHS and the wider economy.
1More

Shortage Of Fluoxetine 10mg Tablets To Continue Till Feb 11 - 0 views

  •  
    Considering the shortage of Fluoxetine 10mg tablets, the Department of Health and Social Care (DHSC) has extended the serious shortage protocol (SSP) for the medicine to February 11, 2022. Earlier the SSP for Fluoxetine 10mg tablets was set to expire on November 12. Extension of the transition period will enable use of No Cheaper Stock Obtainable (NCSO) endorsement and use of EPS tokens to claim for supplies made in accordance with SSPs. The NHS Business Services Authority (NHSBSA) has accepted that either the new 'SSP' or existing 'NCSO' endorsement for any SSP claims can be submitted using electronic prescriptions (EPS) tokens of FP10 paper prescriptions, during the period.
1More

Melatonin: Superdrug Jet Lag Tablets For Travel Portfolio - 0 views

  •  
    Superdrug Online Doctors has made travelling easy ahead of Easter by introducing jet lag 'melatonin' tablets into its travel services portfolio to help those taking long haul flights. The company has seen an 287 per cent increase in demand for its travel services and products. Malaria treatment is up by 272 per cent, gut health products up by 317 per cent, jet lag melatonin tablets increasing by 900 per cent since launch and Period Delay services which offer more choice when it comes to the timing of periods up by 195 per cent year-on-year. Dr Sara Kayat, Superdrug's medical ambassador, comments: "Jet lag is a temporary sleep problem that affects people who travel across different time zones. It can occur when your internal clock, the function that lets your body know when to stay awake and when to sleep, is disrupted by a new time zone and puts your internal clock out of sync. Melatonin is a hormone we produce to help regulate our sleep cycles, and a synthetic version can be taken in the short term to manage jet lag."
1More

HayMax wins 2023 'Global 100' awards | UK News - 0 views

  •  
    HayMax, manufacturer of organic, drug-free allergen barrier balms for hay fever, dust, and pet allergies, has recently won the 2023 Global 100 awards. The HayMax balm, applied around nostril rims and eye bones, is an innovative allergen blocker against pollen, dust, and pet allergens entering the body. Independent university research confirms it traps over a third of pollen, along with dust mites and pet dander, before they enter the body, according to HayMax. The drug-free balm is Soil Association-certified organic, comprising 100 per cent natural ingredients. Safe for children, pregnant, and breastfeeding women, it holds the Vegetarian Society Approved trademark. This award has come as a complete surprise to us at HayMax," said HayMax MD, Max Wiseberg. "Being held in such high regard through this global recognition is truly delightful." "The Global 100 aims to offer readers insight into firms that excel in their chosen specialties, and the award underscores hard work and innovation of various companies," said its organisers.
1More

Addiction Drugs Treat Long Covid Symptoms - 0 views

  •  
    The number of people suffering from addiction is at an all time high, with more people seeking treatment across the USA due to the fentanyl crisis, but new studies have shown that addiction drugs may not only be able to aid those suffering from the deadly disease, but also aid people suffering from long COVID. While there has long been research underway to find a cure for the likes of alcoholism and drug addiction, it turns out naltrexone, a drug used in the addiction treatment space, is helping people who have been suffering from headaches, seizures and fatigue as a result of long COVID. According to Dr. Paul Valbuena at The River Source, an Arizona drug rehab, naltrexone is typically used by rehab centers and prescribed to patients suffering from addiction to reduce cravings and the feeling of euphoria associated with substance use disorder, giving patients clarity and focus to concentrate on recovery. Thanks to a recent report, that has also been revealed to be the case for those suffering with long COVID too, with Lauren Nichols, a long COVID sufferer from Chicago being prescribed the drug by her doctor. She found that the drug helped quell her seizures and headaches, alowing her to think clearly and get on with her life as normal. It's been a similar story for other patients too, and has marked a major breakthrough in the bid to help those who are still suffering in the aftermath of the pandemic.
1More

Dr Sarah Jarvis:EM Pharma welcomes as medical adviser - 0 views

  •  
    Nasofed Anti Viral Nasal Spray, from EM Pharma, is delighted to welcome Dr Sarah Jarvis as medical adviser for its winter colds and flu consumer awareness campaign. Sarah is well known as a trusted and reliable source of medical advice through her various media roles as Resident GP on BBC R2's The Jeremey Vine Show, Good Morning Britain, Channel 5 and ITV News. Says Paul Walsh, EM Pharma Managing Director: "Dr Sarah will be offering advice on how people can best protect themselves and their families against seasonal and year-round viruses, including the use of Nasofed anti viral thixotropic nasal spray as an extra layer of protection particularly in situations of increased viral risk." Dr Sarah adds: "Viruses continue to affect our daily lives, whether that be year-round viruses or more seasonal viruses such as colds and flu and RSV, all of which are expected to be particularly prevalent this year. In situations of increased viral risk, a thixotropic nasal spray delivering anti viral ingredients will help protect you. It's a real step forward in virus prevention, not just for colds and flu, but also year-round viruses."
« First ‹ Previous 861 - 880 of 963 Next › Last »
Showing 20 items per page